ScholarIQanswers from OpenAlex & ORCID
Jong‐Mu Sun
ResearcherPublications, citations & collaboration network
Jong‐Mu Sun is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jong‐Mu Sun have?
ScholarIQindexed works
Jong‐Mu Sun has 128 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jong‐Mu Sun have?
ScholarIQcitation count
Jong‐Mu Sun has 5,558 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jong‐Mu Sun?
ScholarIQh-index
Jong‐Mu Sun has an h-index of 31 in OpenAlex.
What is the i10-index of Jong‐Mu Sun?
ScholarIQi10-index
Jong‐Mu Sun has an i10-index of 62 in OpenAlex.
What is the ORCID of Jong‐Mu Sun?
ScholarIQorcid
The ORCID for Jong‐Mu Sun is on the source record.
What is the OpenAlex record for Jong‐Mu Sun?
ScholarIQopenalex
The OpenAlex for Jong‐Mu Sun is on the source record.
What are the most-cited papers on Jong‐Mu Sun?
ScholarIQmost cited works
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Manel Esteller, Se‐Hoon Lee, Jung Kyoon Choi
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
Pembrolizumab for the treatment of non-small cell lung cancer
Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Sehhoon Park, Chan‐Young Ock, Hyojin Kim, Sérgio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong‐Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung‐Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung‐Jue Bang, Yoon‐La Choi, Tony Mok, Se‐Hoon Lee